Assessment of a compounded synthetic adrenocorticotropic hormone product in 17 healthy dogs

Abstract

ObjectivesSynthetic adrenocorticotropic hormone or tetracosactide is routinely used in the diagnosis of hypoadrenocorticism and frequently in the diagnosis and treatment of hyperadrenocorticism. There have been repeated shortages of tetracosactide in recent years in Australia.This study investigated the agreement of serum cortisol after a compounded tetracosactide (Bova Aus), compared to commercial tetracosactide (Synacthen®) in healthy dogs.MethodsProspective crossover study using 20 dogs. Ten dogs received 5 μg/kg Synacthen® on day 1 and 5 μg/kg compounded tetracosactide on Day 2. The other 10 dogs received the reverse order. Cortisol concentrations in each dog 1 h after injection were compared for agreement, which was defined as the limits of agreement of the Bland–Altman ratio to be within a range of 0.8–1.25. Passing‐Bablok regression analysis examined for constant and proportional biases.ResultsThree dogs were excluded with post‐stimulation serum cortisol concentrations markedly outside reference interval. For the remaining 17 dogs, Bland–Altman ratio analysis of cortisol concentration (tetracosactide/Synacthen®) at 1 h found virtually no constant bias (mean of ratios 1.01;95% CI 0.97–1.05) and 95% limits of agreement were 0.88 (95% CI 0.78–0.90) and 1.17 (95% CI 1.13–1.25). This met our criteria for agreement between cortisol concentrations. Bias of the Bland–Altman difference was 2.8 nmol/L (95% CI −7.2 to 12.8); 95% limits of agreement −35.2 nmol/L (95% CI −57.0 to −26.1) and 40.8 nmol/L (95% CI 31.7–62.6). Passing‐Bablok regression analysis did not identify bias.ConclusionIn healthy dogs, cortisol concentrations were in agreement after compounded tetracosactide compared to commercial tetracosactide, Synacthen®.